Business Description
XSpray Pharma AB
SIC : 2834
ISIN : SE0009973563
Total Employee Number:
24Compare
Compare
Traded in other countries / regions
XSPRAY.Sweden0GHZ.UK6XP.Germany IPO Date
2017-09-28Description
XSpray Pharma AB is a pharmaceutical company focused on developing improved PKIs for cancer treatment, leveraging its proprietary HyNap technology platform. The company aims to enhance clinical outcomes for cancer patients by improving the efficacy, safety, and patient experience of existing cancer therapies. Its product portfolio includes Dasynoc and other product candidates in different stages of development such as XS003 nilotinib, XS008 axitinib, and other.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.22 | |||||
Equity-to-Asset | 0.79 | |||||
Debt-to-Equity | 0.23 | |||||
Debt-to-EBITDA | -1.12 | |||||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 11.7 | |||||
3-Year EPS without NRI Growth Rate | 9.7 | |||||
3-Year FCF Growth Rate | 19.3 | |||||
3-Year Book Growth Rate | -15 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 18.27 | |||||
9-Day RSI | 20.32 | |||||
14-Day RSI | 22.89 | |||||
3-1 Month Momentum % | -13.18 | |||||
6-1 Month Momentum % | -42.96 | |||||
12-1 Month Momentum % | -74.66 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.39 | |||||
Quick Ratio | 1.26 | |||||
Cash Ratio | 1.16 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -21 | |||||
Shareholder Yield % | -69.75 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -26.67 | |||||
ROA % | -20.79 | |||||
ROIC % | -20.43 | |||||
3-Year ROIIC % | -19.15 | |||||
ROC (Joel Greenblatt) % | -179.39 | |||||
ROCE % | -20.47 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 2.81 | |||||
PB Ratio | 0.69 | |||||
Price-to-Tangible-Book | 3.94 | |||||
EV-to-EBIT | -3 | |||||
EV-to-EBITDA | -3.1 | |||||
EV-to-Forward-Revenue | 5.28 | |||||
EV-to-FCF | -2.5 | |||||
| Price-to-Net-Current-Asset-Value | 10.69 | |||||
| Price-to-Net-Cash | 71.54 | |||||
Earnings Yield (Greenblatt) % | -33.42 | |||||
FCF Yield % | -38.57 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
XSpray Pharma AB Executives
DetailsGF Value™
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | |||
| EPS (TTM) (kr) | -3.773 | ||
| Beta | -1.1319 | ||
| 3-Year Sharpe Ratio | 0.04 | ||
| 3-Year Sortino Ratio | 0.06 | ||
| Volatility % | 104.62 | ||
| 14-Day RSI | 22.89 | ||
| 14-Day ATR (kr) | 0.52365 | ||
| 20-Day SMA (kr) | 9.992 | ||
| 12-1 Month Momentum % | -74.66 | ||
| 52-Week Range (kr) | 9.14 - 62.333544 | ||
| Shares Outstanding (Mil) | 47.42 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
XSpray Pharma AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
XSpray Pharma AB Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| Fourth quarter earnings results for 2026 | 2027-02-11 | In 147 days | ||
| Third quarter earnings results for 2026 | 2026-11-04 | In 48 days | ||
| Second quarter earnings results for 2026 | 2026-08-05 | 16.60 (+1.59%) | ||
| General meeting for 2026 | 2026-05-12 10:00 | 24.35 (+2.10%) | ||
| First quarter earnings results for 2026 | 2026-04-28 | 26.90 (-2.00%) | ||
| Annual report for 2025 | 2026-03-26 | 26.74 (+15.06%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-06 | 23.48 (-5.48%) | ||
| Third quarter earnings results for 2025 | 2025-11-05 | 24.21 (-2.16%) | ||
| Second quarter earnings results for 2025 | 2025-08-15 | 46.85 (+0.10%) | ||
| General meeting for 2025 | 2025-05-13 10:00 | 31.95 (+3.24%) |
Show
Entries
XSpray Pharma AB Frequently Asked Questions
What is XSpray Pharma AB(OSTO:XSPRAY)'s stock price today?
The current price of OSTO:XSPRAY is kr9.30. The 52 week high of OSTO:XSPRAY is kr62.33 and 52 week low is kr9.14.
When is next earnings date of XSpray Pharma AB(OSTO:XSPRAY)?
The next earnings date of XSpray Pharma AB(OSTO:XSPRAY) is 2026-11-04.
Does XSpray Pharma AB(OSTO:XSPRAY) pay dividends? If so, how much?
XSpray Pharma AB(OSTO:XSPRAY) does not pay dividend.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers